The recent decision by Sanofi to close the laboratories it acquired in Cambridge, UK, and transfer the work to Boston, US, tells a tale of two cities and highlights the growing competitive gap between them. While both are world-leading academic centers, Boston’s superior commercial ecosystem is proving more attractive for pharmaceutical investment.
The reason for this divergence, according to industry insiders, is policy. A Sanofi executive bluntly stated that the UK is “not a good place to do the development work for medicines” and a “terrible place to sell them.” The commercial environment, shaped by low government spending and outdated pricing, is driving companies away.
In contrast, the Boston area, despite its high costs, benefits from a dynamic market, strong venture capital support, and a more favorable pricing environment in the wider US market. This makes it a more viable place to invest in the expensive, long-term process of drug development.
The Cambridge-to-Boston move is a microcosm of a larger trend. The UK is struggling to translate its scientific excellence into commercial success. To reverse this, it must look at the policies that make hubs like Boston thrive and create a domestic environment that encourages companies to stay and grow.